These are indeed exciting times for spinal cord injury (SCI) clinical trials. There are trials ongoing around the world targeting different repair strategies. In this article we want to take the opportunity to explain some of the high profile clinical trials ongoing in the United States utilizing cells as a therapeutic intervention.

Miami Project Schwann Cells

As many of our readers know, The Miami Projects 1st Phase I clinical trial testing Schwann cells began in November 2012 and we are happy to announce that the final participant was transplanted in August 2015. Schwann cells come from your own body and they are a type of cell found throughout the entire peripheral nervous system (PNS). The PNS includes all nerves going out to muscles as well as sensory nerves coming from the muscles back to the spinal cord. Schwann cells are a type of support cell in the PNS and some important points about Schwann cells are that they 1) insulate (myelinate) individual nerve fibers (axons), which is necessary for sending appropriate electrical signals throughout the nervous system, 2) are not stem cells, they are adult cells and can only be Schwann cells, and 3) can be obtained from each persons own body thereby eliminating the need for immunosuppression medicine.

This trial is specifically targeting people with new SCI, less than 30 days after injury, having sustained a trauma-induced lesion between thoracic levels T3-T11 and whom were neurologically complete. This is a dose escalation treatment trial, meaning that we will test 3 different doses: 5 million, 10 million, and 15 million Schwann cells. There were a total of 39 people screened for eligibility, 9 were enrolled, and 6 participants were transplanted. The first two participants received the 5 million cell dose, the second two received the 10 million cell dose, and the final two received the 15 million cell dose. Thus far, there have been no treatment-related adverse effects in any of the transplanted subjects, which is excellent news. Remember, safety is the determinate of success for this phase I trial. We are not releasing any other information about the participants or results because the trial is still ongoing and we cannot compromise the data. After the final participant is 12 months post-transplant we will prepare the results for publication in a peer-reviewed scientific journal.

Our 2nd Phase I clinical trial began in February 2015 for chronic SCI and will also be primarily focused on safety, but in addition it will involve a preliminary evaluation of the efficacy of combining Schwann cells with exercise and rehabilitation. For humans with chronic SCI, we hypothesize that axons might show improved function if myelin repair is induced with the implantation of autologous Schwann cells. In addition, spinal cord cavitation may be reduced and neural sprouting and plasticity may be enhanced via neurotrophic effects. In this trial, participants will receive three months of fitness conditioning and locomotor rehabilitation prior to transplantation in order to validate the stability of their neurological baseline as well as to enhance their fitness level thereby reducing any deconditioning effects. They will also receive fitness conditioning and rehabilitation for six months post-transplantation to maintain health and promote neuronal activity and potential neuroplasticity. We believe that this combination of cell therapy with intense rehabilitation prior to and following cell transplantation will enhance our chances of seeing improved recovery in the chronic setting https://clinicaltrials.gov/ct2/show/NCT02354625 .

StemCells Inc

Drs. Allan Levi and Kim Anderson, along with several other University of Miami faculty members, are also participating in a clinical trial testing a different cell therapy neural stem cells. That trial, referred to as the Pathway Study, is sponsored by a company called StemCells, Inc.

The Pathway Study is testing the safety and potential benefit of a very specific stem cell type known as a neural stem cell; these are not Schwann cells. The neural stem cells being used in the Pathway Study were derived from fetal brain tissue and have the ability to self-renew and become the main types of mature cells found both in the brain and spinal cord. These cells do not come from your own body, therefore anyone who receives them into their body has to be on immunosuppression medicine. Studies of SCI in animals have shown that these human neural stem cells can survive and lead to recovery of function through remyelination and possibly neuronal cell replacement.

Prior to the Pathway Study, the company conducted a Phase I/II safety & preliminary efficacy clinical trial in humans with thoracic SCI. Twelve participants were transplanted within 3 to 12 months of injury. The results they have disclosed at scientific meetings indicate that neural stem cell transplantation appears to be safe; several participants have regained some sensation.

The Pathway Study is a larger Phase II efficacy clinical trial designed to determine if neural stem cells can help people with cervical SCI recover spinal cord function and gain strength and sensation. They will enroll up to 52 participants. Individuals may be able to join the study if they are 18 to 60 years old, have a cervical SCI that is classified as ASIA Impairment Scale grade A, B, or C, are less than two years post-injury, and are generally in good health. Individuals that are eligible for the study will participate for approximately 12 months. There are several sites around the country that are enrolling https://clinicaltrials.gov/ct2/show/NCT02163876 .

Asterias Biotherapeutics

Many of you have probably heard of the Geron clinical trial that was prematurely halted a few years ago for financial reasons. In 2013, a new company called Asterias Biotherapeutics took over the rights for everything related to the prior trial. The first trial was a Phase I safety trial using a human embryonic stem cell line pre-differentiated into oligodendrocyte progenitor cells. The oligodendrocyte progenitor cells are targeting reduction of the size of the injury cavity as well as remyelination of demyelinated axons to restore conduction. These cells also cannot be obtained from your own body, hence require immunosuppression medicine as well when administered to anyone. In that trial, 5 individuals with complete thoracic injury received the cells within 14 days after their injury. The results they have disclosed at scientific meetings indicate that the cell transplantation appears to be safe and that four of the five participants appear to have a smaller cavity when evaluated by MRI.

In 2015, they began a Phase I/IIa dose escalation trial, the SCI-Star study. This trial is enrolling individuals with cervical injury between levels C5-C7 whom are neurologically complete. The cells have to be injected between 14 to 30 days post-injury; up to 13 participants will receive the cells. There are at least 3 centers enrolling https://clinicaltrials.gov/ct2/show/NCT02302157 .

Neuralstem

The final cell therapy of high profile is being conducted by a company called Neuralstem. This is a Phase I safety trial using human fetal spinal cord neural precursor cells. These stem cells are targeting growth factor replacement and possibly neuronal cell replacement. Again, because these cells do not come from ones own body, they require immunosuppression medicine. The company previously completed a Phase I safety trial using the same cells in individuals with Lou Gehrigs disease. They transplanted 18 participants in mid- to late stages of the disease and demonstrated safety. The company then obtained approval for the SCI Phase I trial. A total of 4 participants with complete thoracic injury, between one and two years post-injury, will be transplanted. The study procedures are all performed in California https://clinicaltrials.gov/ct2/show/NCT01772810 .

To find out more information about the trials being conducted at The Miami Project, contact The Miami Project Education Department at 305-243-7108 or MPinfo@med.miami.edu . More information about all of our clinical trials and studies is available at http://www.themiamiproject.org/trials .

Read the original here:
Exciting Times For Spinal Cord Injury Clinical Trials ...

Spinal Cord Stem Cells Comments Off on Exciting Times For Spinal Cord Injury Clinical Trials … | June 2nd, 2017

A SpaceX rocket is slated to launch two University of Colorado Boulder-built payloads to the International Space Station (ISS) from Florida Thursday, including oneto look at changes in cardiovascular stem cells in microgravity that may someday help combat heart disease on Earth.

The Dragon spacecraft

The second payload will be used for rodent studies testing a novel treatment for bone loss in space, which has been documented in both astronauts and mice. The two payloads were developed by BioServe Space Technologies, a research center within the Ann and H.J Smead Department of Aerospace Engineering,

We have a solid relationship with SpaceX and NASA that allows us to regularly fly our flight hardware to the International Space Station, said BioServe Director Louis Stodieck. The low gravity of space provides a unique environment for biomedical experiments that cannot be reproduced on Earth, and our faculty, staff and students are very experienced in designing and building custom payloads for our academic, commercial and government partners.

The experiments will be launched on a SpaceX Falcon 9 rocket from Cape Canaveral, Florida and carried to the ISS on the companys Dragon spacecraft. The SpaceX-CRS-11 mission launching Thursday marks BioServes 55th mission to space.

The cardiovascular cell experiments, designed by Associate Professor Mary Kearns-Jonker of the Loma Linda University School of Medicine in Loma Linda, California, will investigate how low gravity affects stem cells, including physical and molecular changes. While spaceflight is known to affect cardiac cell structure and function, the biological basis for such impacts is not clearly understood, said BioServe Associate director Stefanie Countryman.

As part of the study, the researchers will be comparing changes in heart muscle stem cells in space with similar cells simultaneously cultured on Earth, said Countryman. Researchers are hopeful the findings could help lead to stem cell therapies to repair damaged cardiac tissue. The findings also could confirm suspicions by scientists that microgravity speeds up the aging process, Countryman said.

For the heart cell experiments, BioServe is providing high-tech, cell-culture hardware known as BioCells that will be loaded into shoebox-sized habitats on ISS. The experiments will be housed in BioServes Space Automated Bioproduct Lab (SABL), a newly updated smart incubator that will reduce the time astronauts spend manipulating the experiments.

The second experiment, created by Dr. Chia Soo of the UCLA School of Medicine, will test a new drug designed to not only block loss of bone but also to rebuild it.

The mice will ride in a NASA habitat designed for spaceflight to the ISS. Once on board, some mice will undergo injections with the new drug while others will be given a placebo. At the end of the experiments half of the mice will be returned to Earth in SpaceXs Dragon spacecraft and transported to UCLA for further study, said Stodieck, a scientific co-investigator on the experiment.

BioServes Space Automated Byproduct Lab

In addition to the two science experiments, BioServe is launching its third SABL unit to the ISS. Two SABL units are currently onboard ISS supporting multiple research experiments, including three previous stem cell experiments conducted by BioServe in collaboration with Stanford University, the Mayo Clinic and the University of Minnesota.

The addition of the third SABL unit will expand BioServes capabilities in an era of high-volume science on board the ISS, said Countryman.

BioServe researchers and students have flown hardware and experiments on missions aboard NASA space shuttles, the ISS and on Russian and Japanese government cargo rockets. BioServe previously has flown payloads on commercial cargo rockets developed by both SpaceX, headquartered in Hawthorne, California, and Orbital ATK, Inc. headquartered in Dulles, Virginia.

Since it was founded by NASA in 1987, BioServe has partnered with more than 100 companies and performed dozens of NASA-sponsored investigations. Itspartners include large and small pharmaceutical and biotechnology companies, universities and NASA-funded researchers, and investigations sponsored by the Center for the Advancement of Science in Space, which manages the ISS U.S. National Laboratory. CU-Boulder students are involved in all aspects of BioServe research efforts, said Stodieck.

More here:
SpaceX to launch heart, bone health experiments to space station Thursday - CU Boulder Today

Cardiac Stem Cells Comments Off on SpaceX to launch heart, bone health experiments to space station Thursday – CU Boulder Today | May 31st, 2017

Two separate research teams have succeeded in generating blood stem cells using completely different procedures. One team was led by stem cell biologist Dr. George Q. Daley of Harvard Medical School and Boston Childrens Hospital. The other team was spearheaded by Dr. Shahin Rafii of the Weill Cornell Medicines Ansary Stem Cell Institute in New York.

In both cases, reprogrammed blood stem cells were able to successfully produce blood cells when implanted into mice. And if either or both procedures turn out to be viable for humans, a future where blood donors will no longer be needed may soon be in the horizon because science has provided us with a way to produce unlimited blood supply.

Stem cells are specially programmed cells that are responsible for creating all of the bodys other cells. There are two types of stem cells embryonic and adult. Embryonic stem cells are located you guessed it in the embryo where they stay before they start to specialise. Adult stem cells are the ones used to repair and replace worn out or old cells.

Those are the natural types. Theres another type, though. Theyre called induced pluripotent stem cells (iPS cells for short). Unlike the first two types, iPS cells arent naturally present. Theyre actually adult stem cells that were converted back to their primitive state, which means they can be coaxed to turn into any type of cell.

Dr. Daley and his team chose to use both embryonic stem cells and iPS cells for their research. Using a combination of proteins, they coaxed the cells to turn into hemogenic endothelium a kind of embryonic tissue that eventually turns into blood stem cells. Next, they tested several transcription factors genes that tell other genes what to do until they came up with the combination (specifically: ERG, HOXA5, HOXA9, HOXA10, LCOR, RUNX1, and SPI1) that pushed the hemogenic endothelium into a blood-forming or blood stem cell state. They then injected those modified cells into the bone marrow of their mice subjects. After several weeks, portions of the mices blood and bone marrow developed different types of blood cells, including red blood cells, white blood cells, and even immune cells.

As Daley described the feat: Were tantalizingly close to generating bona fide human blood stem cells in a dish.

On the other hand, Rafii and his team chose a different route. They didnt make use of iPS cells. Instead, they created true blood stem cells, starting off by extracting stem cells from the blood vessel lining of mature mice. Next, they inserted transcription factors (Fosb, Gfi1, Runx1, and Spi1) into the genomes of the extracted cells, then kept these cells in Petri dishes designed to replicate the environment within human blood vessels.

Over time, the cells turned into blood stem cells and multiplied. They then injected those stem cells into mice treated with radiation (which meant most of their blood and immune cells were gone). The stem cells regenerated not just the blood, but the immune cells too. Consequently, the mice recovered and went on to live for over 1.5 years in the lab.

As described by Rafii, the procedure they used is similar to a direct aeroplane flight, while Daleys is like a flight that took a detour prior to reaching its ultimate destination. Doing away with the iPS part kind of makes Rafiis method slightly better than Daleys because it minimizes the threat of tumors forming or the body rejecting the stem cells, which is a typical reaction that iPS cells might cause. But if Daleys team is able to refine their process to eliminate this risk, then that will level the playing field, so to speak.

Whatever happens from here on, both procedures are nonetheless considered significant breakthroughs. And even though its not yet certain which method will turn out to be the better one for humans, whats clear is that both methods have the potential to be game-changers when it comes to any kind of treatment involving blood infusion and transfusion.

Both studies have been published in the journal Nature, with Daleys under the title Haematopoietic stem and progenitor cells from human pluripotent stem cells and Rafiis under the title Conversion of adult endothelium to immunocompetent haematopoietic stem cells.

Here is the original post:
Scientists Close to Generating Unlimited Blood Supply from Stem Cells - Wall Street Pit

Bone Marrow Stem Cells Comments Off on Scientists Close to Generating Unlimited Blood Supply from Stem Cells – Wall Street Pit | May 31st, 2017

The Hindu

Unrelated donor transplants to aid thalassemics - The Hindu The Hindu A study carried out at Chennai's Apollo Speciality Cancer Hospital now gives hope to children who have no related donors.

Read the original here:
Unrelated donor transplants to aid thalassemics - The Hindu - The Hindu

Bone Marrow Stem Cells Comments Off on Unrelated donor transplants to aid thalassemics – The Hindu – The Hindu | May 30th, 2017

One giant photo looks like a cocoon enmeshed in strands of silk. Another, like a distant nebula as seen by the Hubble Space Telescope. A third brings to mind rivulets of lava pouring down the sides of a volcano atnight.

Yet all of the images in Toronto artist Radha Chaddahs latest exhibition show the same thing: adult-human stem cells that have been reprogrammed to change from skin into neural tissue. The overall effect is similar to taking a voyage through a world that is both utterly exotic yet intimately related to thevoyager.

These are the most striking pictures for me, said Ms. Chaddah, directing attention to a photo in which a cell has been carefully prepared to reveal its cytoskeleton a network of protein fibres that helps maintain shape and function. People dont generally think of cells as having an internalarchitecture.

The Fall.

Courtesy of ArtaGallery

This is not the classic microscope view of the cell, familiar to anyone who has cracked open a high-school biology textbook. Often, the images do not show cell membranes or other recognizable components. Instead, they highlight the hidden structures within cells, which Ms. Chaddah tags with fluorescent antibodies and then blasts with a laser so they glow with vivid colour at the moment she captures the photo. Once the photo is taken, Ms. Chaddah can never go back. So intense are the exposures she requires, that her tiny subjects are destroyed in the act of imagingthem.

Researchers are keen to exploit the potential of stem cells because they can be induced to switch identity. This property holds tremendous promise for regenerative medicine. For example, in the future, a patients skin cells may be reprogrammed and used to help restore ailing vision due to a deterioratingretina.

This is the kind of possibility that Ms. Chaddah was helping to explore when she was a graduate student in cell and molecular biology a decade ago, eventually publishing her work on stem cells in the Journal ofNeuroscience.

Exodus.

courtesy of ArtaGallery

But, like the cells that fascinate her, Ms. Chaddah found herself changing identities. She had started off with training in fine arts and art conservation before going back to school to become a stem-cell researcher. After completing her masters degree, she turned to the arts again, this time with science as herinspiration.

Her current exhibition, which has been on display in Toronto as part of the annual Contact photography festival, is the product of a meeting of those two worlds. As a graduate student, she needed to repeatedly image the cells she was working with a laborious and frequently frustrating process that could sometimes produce results that were beautiful to look at even when they werent scientificallyusable.

I would go into that little microscope room and be lost in there for five or six hours, she said. Then Id come out with zero data, a major headache and a few amazingpictures.

Regents.

Courtesy of ArtaGallery

Recognizing the visual potential of the technique, Ms. Chaddah made a deal with her supervisor, University of Toronto stem-cell scientist Derek van der Kooy: In exchange for some additional research she conducted in the lab, she was given access to the microscope to pursue herart.

I think its a great idea because we look at these cells under the microscope and they look fantastic to us, but they should be fantastic to everyone, Dr. van der Kooysaid.

He added that while he was delighted to see Ms. Chaddahs images appreciated as art, he wished there was more about the science behind them in the exhibition. Ms. Chaddah has taken a less direct route, sparking the viewers curiosity by giving the images biblical titles a choice that is also meant to draw attention to the way medical discoveries can be viewed with something approaching religious reverence. While stem cells are the subject of legitimate research, they have also spurred the desperate to seek miracle treatments based on questionableevidence.

Genesis.

Courtesy of ArtaGallery

Yet, there is also plenty to feed a sense of wonder at the machinery of life. In a piece called Exodus, which is also the name of the exhibition, Ms. Chaddah has captured a neural cell in the act of migration a reminder, she said, that when human cells are cultured in a Petri dish they can revert to acting as individuals rather than as part of a larger organism. On another level, it also refers to the new world of medical benefits and risks that the manipulation of cells is leading us to as asociety.

But even without such layers of meaning, Ms. Chaddah said she is often surprised by the sense of connection her images seem to evoke, even when visitors are not entirely sure what they are looking at as they wander into thegallery.

Its interesting how many people stand amazed in front of these things and they have some feeling that it has something to do with them even before they read that it came from human skin, she said. I want to draw people in with beauty but I would love it if people would think beyond thebeauty.

Covenant.

Courtesy of ArtaGallery.

Exodus is on display until May 31 at the Arta Gallery, 14 Distillery Lane, Toronto, as part of the Scotiabank Contact PhotographyFestival.

Visit link:
Toronto artist exposes the hidden architecture of cells - The Globe ... - The Globe and Mail

Skin Stem Cells Comments Off on Toronto artist exposes the hidden architecture of cells – The Globe … – The Globe and Mail | May 30th, 2017

New York Times

A New Drug for ALS, but the Diagnosis Remains Dire New York Times A.L.S. attacks the nerve cells in the brain and spinal cord that control voluntary muscle movements, like chewing, walking, breathing, swallowing and talking. It is invariably progressive. Lacking nervous system stimulation, the muscles soon begin to ...

Read more:
A New Drug for ALS, but the Diagnosis Remains Dire - New York Times

Spinal Cord Stem Cells Comments Off on A New Drug for ALS, but the Diagnosis Remains Dire – New York Times | May 29th, 2017

UPROXX

This Company Has Pretty Much Invented Harry Potter's 'Skele-Grow' UPROXX EpiBone uses a combination of a patient's own stem cells and a 3D printer in a lab to actually grow new bones in under three weeks. The implications of ... I was growing cardiac and neural tissue, and he was growing bone and cartilage. So this is ...

Follow this link:
This Company Has Pretty Much Invented Harry Potter's 'Skele-Grow' - UPROXX

Cardiac Stem Cells Comments Off on This Company Has Pretty Much Invented Harry Potter’s ‘Skele-Grow’ – UPROXX | May 29th, 2017

The Hindu

Rahman lends his voice for stem cell donation The Hindu Sign up with me as bone marrow donor, Mr. Rahman says, in a short video made by the Jeevan Stem Cell Foundation, which maintains a registry for those in need to find a stem cell match. The video has been uploaded to Youtube ahead of the World Blood ... and more »

More here:
Rahman lends his voice for stem cell donation - The Hindu

Bone Marrow Stem Cells Comments Off on Rahman lends his voice for stem cell donation – The Hindu | May 29th, 2017

FOX31 Denver

Stranger saves life of woman with stem cell transplant FOX31 Denver DENVER -- This is a terrible statistic. Eighty percent of blood cancer patients in need of stem cell or bone marrow transplant are not able to get one, in part because they can't find a match. But you can help change that and save a life by registering ...

Continue reading here:
Stranger saves life of woman with stem cell transplant - FOX31 Denver

Bone Marrow Stem Cells Comments Off on Stranger saves life of woman with stem cell transplant – FOX31 Denver | May 27th, 2017

May 24, 2017 by Collene Ferguson Jeff Biernaskies research identifies a factor essential for dermal stem cells to continuously divide during tissue regeneration. Credit: Riley Brandt, University of Calgary

Stem cell researchers at the University of Calgary have found another piece of the puzzle behind what may contribute to hair loss and prevent wounds from healing normally.

Jeff Biernaskie's research, published recently in the scientific journal npj Regenerative Medicine identifies a key signalling protein called platelet-derived growth factor (PDGF). This protein is critical for driving self-renewal and proliferation of dermal stem cells that live in hair follicles and enable their unique ability to continuously regenerate and produce new hair.

"This is the first study to identify the signals that influence hair follicle dermal stem cell function in your skin," says Biernaskie, an associate professor in comparative biology and experimental medicine at the University of Calgary'sFaculty of Veterinary Medicine, and Calgary Firefighters Burn Treatment Society Chair in Skin Regeneration and Wound Healing. Biernaskie is also a member of the Alberta Children's Hospital Research Institute.

"What we show is that in the absence of PDGF signalling hair follicle dermal stem cells are rapidly diminished because of their inability to generate new stem cells and produce sufficient numbers of mature dermal cells within the hair follicle."

Biernaskie and his team of researchers study dermal stem cells located within hair follicles. They are looking to better understand dermal stem cell function and find ways to use these cells to develop novel therapies for improved wound healing after injury, burns, disease or aging.

This study, co-authored byRaquel Gonzalez and Garrett Moffatt,shows that PDGF is key to maintaining a well-functioning stem cell population in skin. And in normal skin, if you don't have enough of it the stem cell pools start to shrink, meaning eventually the hair will no longer grow and wounds will not heal as well.

"It's an important start in terms of how we might modulate these cells towards developing future therapies that could regenerate new dermal tissue or maintain hair growth" says Biernaskie.

Biernaskie's lab is looking at the potential role of stem cells in wound healing and the potential to stimulate these cells to improve skin regeneration, as opposed to forming scars.

Explore further: Using stem cells to grow new hair

More information: Raquel Gonzlez et al. Platelet-derived growth factor signaling modulates adult hair follicle dermal stem cell maintenance and self-renewal, npj Regenerative Medicine (2017). DOI: 10.1038/s41536-017-0013-4

In a new study from Sanford-Burnham Medical Research Institute (Sanford-Burnham), researchers have used human pluripotent stem cells to generate new hair. The study represents the first step toward the development of a cell-based ...

If the content of many a situation comedy, not to mention late-night TV advertisements, is to be believed, there's an epidemic of balding men, and an intense desire to fix their follicular deficiencies.

UT Southwestern Medical Center researchers have identified the cells that directly give rise to hair as well as the mechanism that causes hair to turn gray findings that could one day help identify possible treatments ...

Researchers in the Perelman School of Medicine at the University of Pennsylvania have determined the role of a key growth factor, found in skin cells of limited quantities in humans, which helps hair follicles form and regenerate ...

(Medical Xpress)A European team of researchers working at Sweden's Karolinska Institutet has found evidence that suggests that humans have an olfactory defense against contagious diseases. In their paper published in Proceedings ...

Stem cell researchers at the University of Calgary have found another piece of the puzzle behind what may contribute to hair loss and prevent wounds from healing normally.

Scientists at the University of Sheffield have developed a new technique to examine human sperm without killing themhelping to improve the diagnosis of fertility problems.

The average human pair of lungs is permeated by a network of about 164 feet of blood vessels (roughly the width of a football field), including microscopic blood capillaries, which facilitate the diffusion of oxygen into ...

Researchers from Princeton University's Department of Molecular Biology have identified a small RNA molecule that helps maintain the activity of stem cells in both healthy and cancerous breast tissue. The study, which will ...

A multi-institutional team based at Massachusetts General Hospital (MGH) has discovered how a potential treatment strategy for Huntington disease (HD) produces its effects, verified its action in human cells and identified ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more from the original source:
Researchers identify 'signal' crucial to stem cell function in hair follicles - Medical Xpress

Skin Stem Cells Comments Off on Researchers identify ‘signal’ crucial to stem cell function in hair follicles – Medical Xpress | May 24th, 2017

Todd J. Herron, BS, PhD Director of the Frankel Cardiovascular Center's Cardiovascular Regeneration Core Laboratory and Assistant Research Professor at the University of Michigan Center for Arrhythmia

Yorba Linda, Ca (PRWEB) May 23, 2017

Pluripotent stem cells (PSCs) offer an unlimited source of human cardiovascular cells for research and the development of cardiac regeneration therapies. The development of highly efficient cardiac-directed differentiation methods makes it possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due to varying differentiation efficiencies, further enrichment of CM populations for downstream applications is essential.

Recently, a CM-specific cell surface marker called SIRPa (signal-regulatory protein alpha, also termed CD172a) was reported to be a useful tool for flow sorting of human stem cellderived CMs. However, our expression analysis revealed that SIRPa only labels a subpopulation of CMs indicated by cardiac Troponin T (cTnT) expression. Moreover, SIRPa is also expressed on a sub population of non-CMs, hence making SIRa an inadequate marker to enrich PSC-derived CMs.

In this webinar, sponsored by the team at Miltenyi Biotec, participants will have a chance to review human induced pluripotent stem cell derivation, cardiac directed differentiation to human pluripotent stem cell cardiomyocytes (hPSC-CMs), enrichment of hPSC-CMs and subsequent formation of 2D monolayers of electrically connected cells. They will also learn of the generation of purified human induced pluripotent stem cell derived cardiomyocyte.

The speaker for this event will be Dr. Todd J. Herron, director of the Frankel Cardiovascular Center's Cardiovascular Regeneration Core Laboratory and Assistant Research Professor at the University of Michigan Center for Arrhythmia Research.

Herron currently serves as the director of the Frankel Cardiovascular Center's Cardiovascular Regeneration Core Laboratory, as well as holding a position on the faculty in the University of Michigan Medical School and has appointments in the Department of Internal Medicine and Molecular & Integrative Physiology as Associate Research Scientist. His research is focused on the complex interplay between cardiac electrical excitation and contractile force generation-a process known classically as excitation-contraction coupling.

LabRoots will host the event June 7, 2017, beginning at 9 a.m. PDT, 12 p.m. EDT. To read more about this event, learn about the continuing education credits offered, or to register for free, click here.

ABOUT MILTENYI BIOTEC Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The companys innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Miltenyi Biotecs technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Their more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In their commitment to the scientific community, Miltenyi Biotec also offers comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 1,500 employees in 25 countries all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.

ABOUT LABROOTS LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the worlds largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

Share article on social media or email:

Read more from the original source:
Miltenyi Biotec Showcases the Generation of Purified Human iPSC Derived Cardiomyocytes - PR Web (press release)

Cardiac Stem Cells Comments Off on Miltenyi Biotec Showcases the Generation of Purified Human iPSC Derived Cardiomyocytes – PR Web (press release) | May 23rd, 2017

BENGALURU:Full-fledged treatment for cancer and bone-related ailments using stem-cell within the state could soon be a possibility if a plan of a world renowned surgeon from the state succeeds.

Dr A A Shetty is a highly decorated orthopedic surgeon and professor based in the UK who won the Nobel equivalent of surgery called the Hunterian Medal, this year. In his aim to bring about next level cancer and orthopedic treatment, he has already set up two big stem cell research labs - one in Dharwad and another in Mangaluru, a few years back at a cost of around 20 to 25 crore. A hospital that will treat stem-related ailments has also been envisaged at a total cost of around Rs 200 to 250 crore.

Setting up the labs is part of a three-step goal. After setting up the labs, the next step will be producing the stem cells, whether it be for bone ailments, treatment for cervical cancer etc. Then the third step will be the application of these stem cells through our hospital or through tie-ups with other hospitals. I have already received the funding for setting up the hospital, says Dr Shetty in an interaction with CE in Bengaluru. He is originally from a small village called Asode in Udupi district.

The lab in Dharwad is located at SDM College and is being backed by Shri Dharmasthala Manjunatheshwara and will be primarily working on blood cancer and thalassemia treatment. The one in Mangaluru is located at K.S. Hegde Medical Academy (KSHEMA) and is backed by the NITTE group. It will work on cartilage and bone fracture treatments.The effort is no doubt for profit. We will charge the rich but the poor will be treated for free at our hospital, he says.

Already, Shetty has recruited a number of top stem cell researchers from the state who are presently abroad. I have recruited researchers who were doing their postdoc studies in Japan, South Korea. Presently there are four of them working at the two labs, he says. Shetty ultimately wants to settle in Karnataka and hopes to achieve his goal by 2020. The third stage of his plan also requires expertise in various cutting edge technologies such as robotics, computing and he will also be recruiting people who specialize in these fields.

Cancer Vaccination

Shetty also hopes to make cancer vaccination a possibility. Giving an example of cervical cancer, Shetty says, Few cancers can be vaccinated. Cervical cancer, one of the most rampant cancers, is one of them. We will use stems derived from iPS cell. In the UK, the vaccine cost 60 pounds. Our aim is to develop it and sell it at a very low cost, as low as Rs 100, he adds. Induced Pluripotent Stem Cells or iPS Cells are derived from the blood and skiwwn cells and can be reprogrammed to provide an unlimited source of any type of human cell.

Stem cells for Arthritis In 2013, Shetty devised a minimally invasive procedure to treat arthritis using stem cells. When the cartilage between the bones begin to erode, the bones rub against each other and cause severe pain. Shetty treated a patient suffering from knee arthritis. He drilled a hole into the patients knee bone and released stem cells that could grow into the cartilage. In all, the procedure lasted just 30 minutes. Shetty has already done as many as two dozen such procedures in India.

Trauma Center Shetty also says that he wants to develop and provide integrated trauma services. If a patient survives the golden hour then he/she can be saved. Majority die in the first hour of trauma. My integrated services will have specialized suits that will help reduce blood loss and will have other know-how. I am negotiating with the International Rotary on this, he adds. This may be established either in Mangalore or Bangalore.

Dr Vishal Rao, head and neck oncology surgeon at HCG Hospitals says that stem cells research is in the mid-stage of development and has great potential to grow in India. The IT and BT ministry is already taking great steps by encouraging startups on these lines, starting various schemes, he says. Vishal also pointed out that a number of private organizations, hospitals and individuals like those like Dr Shetty are also investing in the field.

Read the rest here:
Stem-cell therapy for cancer comes closer home - The New Indian Express

IPS Cell Therapy Comments Off on Stem-cell therapy for cancer comes closer home – The New Indian Express | May 23rd, 2017

With gene-editing techniques such as CRISPR-Cas9, offending genes could one day be snipped out of hematopoietic stem cells, then be returned to their owners to generate new lines of disease-free blood cells

New research has nudged scientists closer to one of regenerative medicines holy grails: the ability to create customised human stem cells capable of forming blood that would be safe for patients. Advances reported in the journal Nature could not only give scientists a window on what goes wrong in such blood cancers as leukaemia, lymphoma and myeloma, but they could also improve the treatment of those cancers, which affect some 1.2 million Americans. The stem cells that give rise to our blood are a mysterious wellspring of life. In principle, just one of these primitive cells can create much of a human beings immune system, not to mention the complex slurry of cells that courses through a persons arteries, veins and organs. While the use of blood-making stem cells in medicine has been common since the 1950s, it remains pretty crude. After patients with blood cancers have undergone powerful radiation and chemotherapy treatments to kill their cancer cells, they often need a bone-marrow transplant to rebuild their white blood cells, which are destroyed by that treatment. The blood-making stem cells that reside in a donors bone marrow and in umbilical cord blood that is sometimes harvested after a babys birth are called hematopoietic, and they can be life-saving. But even these stem cells can bear the distinctive immune system signatures of the person from whom they were harvested. As a result, they can provoke an attack if the transplant recipients body registers the cells as foreign. This response, called graft-versus-host disease, affects as many as 70 percent of bone-marrow transplant recipients in the months following the treatment, and 40 percent develop a chronic version of the affliction later. It can overwhelm the benefit of a stem cell transplant. And it kills many patients. Rather than hunt for a donor whos a perfect match for a patient in need of a transplant a process that can be lengthy, ethically fraught and ultimately unsuccessful doctors would like to use a patients own cells to engineer the hematopoietic stem cells. The patients mature cells would be reprogrammed to their most primitive form: stem cells capable of becoming virtually any kind of human cell. Then factors in their environment would coax them to become the specific type of stem cells capable of giving rise to blood. Once reintroduced into the patient, the cells would take up residence without prompting rejection and set up a lifelong factory of healthy new blood cells. If the risk of deadly rejection episodes could be eliminated, physicians might also feel more confident treating blood diseases that are painful and difficult but not immediately deadly diseases such as sickle cell disease and immunological disorders with stem cell transplants. The two studies published on Wednesday demonstrate that scientists may soon be capable of pulling off the sequence of operations necessary for such treatments to move ahead. One of two research teams, led by stem cell pioneer Dr George Q. Daley of Harvard Medical School and the Dana Farber Cancer Institute in Boston, started their experiment with human pluripotent stem cells primitive cells capable of becoming virtually any type of mature cell in the body. Some of them were embryonic stem cells and others were induced pluripotent stem cells, or iPS cells, which are made by converting mature cells back to a flexible state. The scientists then programmed those pluripotent stem cells to become endothelial cells, which line the inside of certain blood vessels. Past research had established that those cells are where blood-making stem cells are born. Here, the process needed a nudge. Using suppositions gleaned from experiments with mice, Daley said his team confected a special sauce of proteins that sit on a cells DNA and programme its function. When they incubated the endothelial cells in the sauce, they began producing hematopioetic stem cells in their earliest form. Daleys team then transferred the resulting blood-making stem cells into the bone marrow of mice to see if they would take. In two out of five mice who got the most promising cell types, they did. Not only did the stem cells establish themselves, they continued to renew themselves while giving rise to a wide range of blood cells. A second research team, led by researchers from Weill Cornell Medicines Ansary Stem Cell Institute in New York, achieved a similar result using stem cells from the blood-vessel lining of adult mice. After programming those cells to revert to a more primitive form, the scientists also incubated those stem cells in a concoction of specialised proteins. When the team, led by Raphael Lis and Dr Shahin Rafii, transferred the resulting stem cells back into the tissue lining the blood vessels of the mice from which they came, that graft also took. For at least 40 weeks after the incubated stem cells were returned to their mouse owners, the stem cells continued to regenerate themselves and give rise to many blood-cell types without provoking immune reactions. In addition to making a workhorse treatment for blood cancers safer, the new advances may afford scientists a unique window on the mechanisms by which blood diseases take hold and progress, said Lee Greenberger, chief scientific officer for the Leukemia and Lymphoma Society. From a research point of view you could now actually begin to model diseases, said Greenberger. If you were to take the cell thats defective and make it revert to a stem cell, you could effectively reproduce the disease and watch its progression from the earliest stages. That, in turn, would make it easier to narrow the search for drugs that could disrupt that disease process early. And it would speed the process of discovering which genes are implicated in causing diseases. With gene-editing techniques such as CRISPR-Cas9, those offending genes could one day be snipped out of hematopoietic stem cells, then be returned to their owners to generate new lines of disease-free blood cells. But Daley cautioned that significant hurdles remain before studies like these will transform the treatment of blood diseases. We do know the resulting cells function like blood stem cells, but they still are at some distance, molecularly, from native stem cells, he said. By tinkering with the processes by which pluripotent stem cells mature into blood-producing stem cells, Daley said his team hopes to make these lab-grown cells a better match for the real things. Los Angeles Times/TNS

More:
Regenerative medicine: holy grail within grasp? - Gulf Times

Bone Marrow Stem Cells Comments Off on Regenerative medicine: holy grail within grasp? – Gulf Times | May 21st, 2017

Athlone mother's desperate search for bone marrow donor for son (3)

Raqeeb Palm was diagnosed with Aplastic Anaemia in October after his mother noticed unusual bruises on his body.

Three-year-old Raqeeb Palm was diagnosed with Aplastic Anaemia in October after his mother noticed unusual bruises on his body. Picture: Monique Mortlock/EWN.

CAPE TOWN A mother from Heideveld in Athlone is desperately trying to find a bone marrow donor for her three-year-old son.

Raqeeb Palm was diagnosed with Aplastic Anaemia in October after his mother noticed unusual bruises on his body.

The boy had to undergo various blood tests and two bone marrow biopsies over a two-month period, before being diagnosed with the rare disease which damages bone marrow and stem cells.

Zaida Palm says her outgoing child can no longer play outside or do many of the activities three-year-olds enjoy due to his severely weakened immune system.

Hes got practically no immune system. So going out, malls, play areas, doing fun things is on a stop. Because any germ, he gets admitted [to the hospital] for a cold, he needs to go to the hospital.

Palm says they have been unable to find a bone marrow donor in South Africa.

A transplant is her son's only chance of survival.

Her medical aid won't cover an investigation for international donors, which is why she's turned to online crowd-funding.

The hundred thousand on the Backabuddy [website] is just the start to the campaign.

Palm has also urged people to become bone marrow donors.

However, we will NOT condone the following:

- Racism (including offensive comments based on ethnicity and nationality) - Sexism - Homophobia - Religious intolerance - Cyber bullying - Hate speech - Derogatory language - Comments inciting violence.

We ask that your comments remain relevant to the articles they appear on and do not include general banter or conversation as this dilutes the effectiveness of the comments section.

We strive to make the EWN community a safe and welcoming space for all.

EWN reserves the right to: 1) remove any comments that do not follow the above guidelines; and, 2) ban users who repeatedly infringe the rules.

Should you find any comments upsetting or offensive you can also flag them and we will assess it against our guidelines.

EWN is constantly reviewing its comments policy in order to create an environment conducive to constructive conversations.

Follow this link:
Athlone mother's desperate search for bone marrow donor for son (3) - Eyewitness News

Bone Marrow Stem Cells Comments Off on Athlone mother’s desperate search for bone marrow donor for son (3) – Eyewitness News | May 20th, 2017

Heavy increases in obesity have led to an epidemic of various heart diseases, including cardiac arrests and even strokes. These dangers have compelled doctors and research specialists to seek out new ways of managing these problems. One method that has been getting a lot of attention is regenerative medicine.

This treatment method, while occasionally controversial, shows an incredible potential that could solve many serious health problems. Specialists like Dr. Cameron Clokie, a health expert with decades of experience, are currently trying to find ways to make this treatment method more accepted by those who oppose it.

The Potential for Serious Health Benefits is Huge

Regenerative medicine is the use of stem cells and other regeneration items to promote more efficient healing. Dr. Cameron Clokie has preached about the effectiveness of this treatment method for years. And it seems like the rest of the world is finally catching up with him and others like him. For example, a recent study found that stem cells could help manage cardiac and nervous system diseases.

The careful use of stem cells could regenerate damaged heart tissues and help a person avoid heart attacks and other serious problems. Even more promising, stem cells could be used to help repair nerve damage that would otherwise leave a person paralyzed for life.

Stem Cell Research Could Save Lives

Think of the stem cells in your body as building blocks that will take whatever shape is necessary. They can become heart cells and patch a hole in this vital organ. However, they could also become spinal cells and repair severe damage to this crucial part of the body.

The possibilities associated with stem cells could be potentially limitless. As they can be manipulated to take the form of any cell, they could be used to treat a variety of serious health problems. For example, they could become white blood cells and fight serious viral problems. In fact, they could even be used to treat life-threatening diseases like AIDS.

One of the understated benefits of regenerative medicine is the way that it uses actual cells from your body. Think of the problems the medical world has had with artificial hearts. While they can be beneficial to many people, they are often rejected by the fickle body as an intruder. However, creating a working heart with your body's stem cells would eliminate that problem.

Why? Your body would recognize the heart's cells as coming from you and would accept it more readily. As a result, you could get a new (and real) heart to replace a severely damaged one.

Profit Levels Could Also Be High

One thing that has interested many people about regenerative health and stem cell research is the potential for huge profits. Many health experts have tried to stress the ways that regenerative health could help boost the world's economy. For example, a recent study on the financial state of this market found that it had an $18.9 billion global impact.

Even more shocking, it was projected to hit $53 billion by 2021. The major focus of this market would be in bone and joint reconstruction. The United States was expected to potentially make the largest profits in this area, which is something Dr. Cameron Clokie has emphasized in the past.

However, the European market is projected to be even bigger if the currently somewhat stagnant American regenerative market is held back by restrictive regulations or laws. In this way, well-meaning politicians could deny their constituents access to lifesaving treatments and severely impact the market at the same time.

Final Thoughts

Regenerative medicine of the type proposed by Dr. Cameron Clokie and others like him could transform the medical world. While the protests of people who find stem cells wrong are understandable, the major benefits of using them cannot be ignored.

This fact is why it is so important to help specialists like Dr. Cameron Clokie get the help they need to promote regenerative medicine breakthroughs. In this way, it is possible to solve serious health dangers.

Visit link:
Canadian Doctors Like Cameron Clokie Are The Innovators Behind The New Era of Regenerative Medicine - French Tribune

Cardiac Stem Cells Comments Off on Canadian Doctors Like Cameron Clokie Are The Innovators Behind The New Era of Regenerative Medicine – French Tribune | May 19th, 2017

New research has nudged scientists closer to one of regenerative medicines holy grails: the ability to create customized human stem cells capable of forming blood that would be safe for patients.

Advances reported Wednesday in the journal Nature could not only give scientists a window on what goes wrong in such blood cancers as leukemia, lymphoma and myeloma. They could also improve the treatment of those cancers, which affect some 1.2 million Americans.

The stem cells that give rise to our blood are a mysterious wellspring of life. In principle, just one of these primitive cells can create much of a human beings immune system, not to mention the complex slurry of cells that courses through a persons arteries, veins and organs.

While the use of blood-making stem cells in medicine has been common since the 1950s, it remains pretty crude. After patients with blood cancers have undergone powerful radiation and chemotherapy treatments to kill their cancer cells, they often need a bone-marrow transplant to rebuild their white blood cells, which are destroyed by that treatment.

The blood-making stem cells that reside in a donors bone marrow and in umbilical cord blood that is sometimes harvested after a babys birth are called hematopoietic, and they can be life-saving. But even these stem cells can bear the distinctive immune system signatures of the person from whom they were harvested. As a result, they can provoke an attack if the transplant recipients body registers the cells as foreign.

This response, called graft-versus-host disease, affects as many as 70% of bone-marrow transplant recipients in the months following the treatment, and 40% develop a chronic version of the affliction later. It can overwhelm the benefit of a stem cell transplant. And it kills many patients.

Rather than hunt for a donor whos a perfect match for a patient in need of a transplant a process that can be lengthy, ethically fraught and ultimately unsuccessful doctors would like to use a patients own cells to engineer the hematopoietic stem cells.

The patients mature cells would be reprogrammed to their most primitive form: stem cells capable of becoming virtually any kind of human cell. Then factors in their environment would coax them to become the specific type of stem cells capable of giving rise to blood.

Once reintroduced into the patient, the cells would take up residence without prompting rejection and set up a lifelong factory of healthy new blood cells.

If the risk of deadly rejection episodes could be eliminated, physicians might also feel more confident treating blood diseases that are painful and difficult but not immediately deadly diseases such as sickle cell disease and immunological disorders with stem cell transplants.

The two studies published Wednesday demonstrate that scientists may soon be capable of pulling off the sequence of operations necessary for such treatments to move ahead.

One of two research teams, led by stem-cell pioneer Dr. George Q. Daley of Harvard Medical School and the Dana Farber Cancer Institute in Boston, started their experiment with human pluripotent stem cells primitive cells capable of becoming virtually any type of mature cell in the body. Some of them were embryonic stem cells and others were induced pluripotent stem cells, or iPS cells, which are made by converting mature cells back to a flexible state.

The scientists then programmed those pluripotent stem cells to become endothelial cells, which line the inside of certain blood vessels. Past research had established that those cells are where blood-making stem cells are born.

Here, the process needed a nudge. Using suppositions gleaned from experiments with mice, Daley said his team confected a special sauce of proteins that sit on a cells DNA and program its function. When they incubated the endothelial cells in the sauce, they began producing hematopioetic stem cells in their earliest form.

Daleys team then transferred the resulting blood-making stem cells into the bone marrow of mice to see if they would take. In two out of five mice who got the most promising cell types, they did. Not only did the stem cells establish themselves, they continued to renew themselves while giving rise to a wide range of blood cells.

A second research team, led by researchers from Weill Cornell Medicines Ansary Stem Cell Institute in New York, achieved a similar result using stem cells from the blood-vessel lining of adult mice. After programming those cells to revert to a more primitive form, the scientists also incubated those stem cells in a concoction of specialized proteins.

When the team, led by Raphael Lis and Dr. Shahin Rafii, transferred the resulting stem cells back into the tissue lining the blood vessels of the mice from which they came, that graft also took. For at least 40 weeks after the incubated stem cells were returned to their mouse owners, the stem cells continued to regenerate themselves and give rise to many blood-cell types without provoking immune reactions.

In addition to making a workhorse treatment for blood cancers safer, the new advances may afford scientists a unique window on the mechanisms by which blood diseases take hold and progress, said Lee Greenberger, chief scientific officer for the Leukemia and Lymphoma Society.

From a research point of view you could now actually begin to model diseases, said Greenberger. If you were to take the cell thats defective and make it revert to a stem cell, you could effectively reproduce the disease and watch its progression from the earliest stages.

That, in turn, would make it easier to narrow the search for drugs that could disrupt that disease process early. And it would speed the process of discovering which genes are implicated in causing diseases. With gene-editing techniques such as CRISPR-Cas9, those offending genes could one day be snipped out of hematopoietic stem cells, then be returned to their owners to generate new lines of disease-free blood cells.

Excerpt from:
Scientists get closer to making personalized blood cells by using patients' own stem cells - Los Angeles Times

Bone Marrow Stem Cells Comments Off on Scientists get closer to making personalized blood cells by using patients’ own stem cells – Los Angeles Times | May 18th, 2017

Science Daily

Engineered bone marrow could make transplants safer Science Daily Bone marrow transplants are used to treat patients with bone marrow disease. Before a transplant, a patient is first given doses of radiation, sometimes in combination with drugs, to kill off any existing stem cells in the patient's bone marrow. This ... Engineered Bone Marrow Improves Transplant SafetyR & D Magazine Engineered bone marrow may ease transplants - The San Diego ...The San Diego Union-Tribune all 4 news articles »

Read the original post:
Engineered bone marrow could make transplants safer - Science Daily

Bone Marrow Stem Cells Comments Off on Engineered bone marrow could make transplants safer – Science Daily | May 14th, 2017

2016.09.20 MEDIAAlvetex wins CV Technology Innovator Awards 2016

ReproCELL is proud to announce its groundbreaking 3D cell culture technology Alvetex has been awarded the Corporate Vision Technology Innovator Award 2016. Read the full interview with Prof. Dr. Stefan Przyborski, ReproCELL Europes Chief Scientific Officer and inventor of Alvetex, here: http://reinnervate.com/reprocell-europe-wins-cv-tech-innovator-awards-2016-alvetex/

We will exhibit and presentat a poster at ISSCR 2016 Annual Meeting, San Francisco, USA. We will like to welcome you to stop by our booth and posters. ISSCR 2016 Annual Meeting URL http://www.isscr.org/home/annual-meeting/san-francisco-2016 Date JUNE 22-25, 2016 Place San Francisco, America Booth: Date JUNE 22-25, 2016 Booth No. 1608 POSTER Date & Time JUNE 22, 2016630PM730PM Poster No. Poster W1093 Title Improvement of human iPS cell-derived hepatocyte functionality using 3D culture systems Presenter ReproCELL, Inc. Zachary Yu Ching Lin Date & Time JUNE 22, 2016730PM830PM Poster No. Poster W2064 Title Non-modified RNAs for the derivation of clinically relevant iPS cell lines from adult []

We make the presentation a poster at 11th International ISSX Meeting at Busan, Korea. Please stop by at our poster if you attend to the meeting. 11th International ISSX Meeting URL http://issxbusan2016.org/ Date June 12-16, 2016 Place Busan, Korea POSTER Date June 15, 201612151300Poster session 2 Location Exhibit Hall (Grand Ballroom 3F) Poster No. P52 Title Stabilized and Enhanced CYP450 Enzyme Activity in Cultured Human Primary Hepatocytes is Conferred by ReproHP Medium Host Sales & Marketing DepartmentPaul CIZDZIEL Wirtz Julia POSTER Date June 15, 201612151300Poster session 2 Location Exhibit Hall (Grand Ballroom 3F) Poster No. P232 Title Improving the prediction of oral bioavailability using fresh []

Webinar: iPSC derived Cells & hiPSC/ES media June 4th 2013 10 AM CEST Please register from here; https://attendee.gotowebinar.com/register/7334590631056470272

ReproCELLs iPS cell technology featured in NHK World news http://www3.nhk.or.jp/nhkworld/english/movie/feature201303211118.html

An article written jointly by Kyoto University and ReproCELL was published in Cell Rep. 2012 Nov 29;2(5):1448-60.. Small Molecule that Promotes Cardiac Differentiation of Human Pluripotent Stem Cells under Defined, Cytokine- and Xeno-free Conditions

ReproCELLs iPS cell business was widely introduced in Japanese TV news on Prof. Shinya Yamanakas Nobel Prize.

ReproCELLs iPS cell-derived cardiomyocytes, neurons and hepatocytes were introduced in Genetic Engineering & Biotechnology News (GEN). Jan 15, 2012 (Vol. 32, No. 2) Stem Cell Applications Hasten into the Clinic

An article in Genetic Engineering & Biotechnology News, Pharmas R&D Focus Shifting to Stem Cells -Investors Interest in These Cells Increases as Scientists Continue to Unleash Their Potential introduces ReproCELLs new cardiotoxicity assay using iPSCs, QTempo, as well as its neural stem cell research. Read the article

Go here to read the rest:
ReproCELL - Stem Cell Innovation

IPS Cell Therapy Comments Off on ReproCELL – Stem Cell Innovation | May 14th, 2017

rG0{2)%H{fQ.-}! w?EFlfVuWj6|Xl5*+oUWx&g9U}YaA(FQ@88h4qPwE`-3sHG^jJqWUnmqaabwO,qkB5f{vlsGL#ql9?QakUloW?v,e;=k; vYC6WK^|1> |%@ 0!P Nbalx3XUWE`CQN`/g@,aC j9.Ac@Kj0S[.nzVWShnE-'X3z^r@ -/O|YWF/fWu&@'GkC )B9x Z[E%<`yfM5*[u",5J;:S0AK?0@6 uZj ,XIM8!6o`00z>27~0xW^zkhiW_ROX@K;5E(=G}zB<'a]V:exmv7j:;kYAu}a*cnNP{*{.tQjNv-< h)GG@TR~TsQ-?tQ=SU,~f?UY,OA-t3@G1E}i~R##(p+B^|~h<!^&Y)3*Lsl{Lgu7H=2^S2 pp D!=f[G{hp3GZOLmIQl/8U*]Lase= yfX$-(v%ZSks.w+Xp 8rZ&=W|q -; oznYpk7h:2o96:s%o}KP]G?X6:iizRo(#tZsoA^< m2^[xcE8[rz:f'IaO"4ZZ(]ap4>7v-qKv(F2G9@ ,~fS#0va04elk%r6fZc#M=2N|B EYWE ;L|6xzCo;@m#hoYzFgGkWXa{3h8|3 }~tp>as =D[5c.%_F(<_V^>G-Z^69k5M*~p:,OiA]M(B hQ169]([0g3Brb3Ubj`kU79cbm*TX8,Ohs/hjTZE~6te:D{(~%++42T# 9F6-en_A}6@ IZ suAMR1(oRgJI-u+YQQ%9iy}avP"7Wa| ~-ixq#`}WFn wWo/a6@)L0c;r8d'W/ht7ZG/@i565!Yz%?JVo o-Ge A-l6 GcmOACG'~IDW4D36ZQ+ ]`|&"jVyvN&FM6ta%KD53qJwS{Ok5[MAeh2EGJ=WM-Ah)z6}l=5}PmDQn7@]dndS/~Le%P)`x#O'`8xlV`8Fwz :Ct$o+Mej5rSHpmX d=egM-U(ZCx8MXj9J>U--d5 56TA*`37A{a@YhY(u !w Y2/*#6OfR4;BHkmi_Mm+O]0V"w]s04ecKter#`olYlK#f1-a-sSYU;Rh@pGmN1KGro 4S7y(nE!^o3f^o`R)@K<)<-}}j6,?,w!<1M7E= C.O/l&XoE iqiDNvHEeg{7o@IUl>YE{'qMK tQ }0h)C#5/5C#0Vnuno &|T3Pzg#f9 P{@8I!6ooW-"K 8~ NDQnUUY:h?_wwFU}_5;rYk{aV2wzuyWbqQ8E.A_?#ooDB6][=-AO:^-TaR1%F}X%%dE ,zb*/Lk{ ZhuRf%P?hte>mi?$.jyx*`PkiZbrV6[@6ci,>Kv;Er.s:jrtpd~mn=KiK ~Y%jCasXu@aPg=^Hmx@?~ K4Pz[ztqt p*:O# CqvJwTzMxy6wG8ajH!'$;Q"6?krG#3Es(8'PN5`kQnz2F;F}tw u^C=Zm#0@-u U|9;8%z^mhm~r< I1*yq!IagP1>`'X#TWue+T;e1YTW5@Mx?f+caek9*V5[}S&zY]R|y6zVHgJm(O*.U V=}uOz< I ElrQt&"DH)_)&nU6rq}yE)H5 dyvX%# RlcP6VvT$bo&fYf2'heG2MED&bOSa:www3v.v)Ge"&7*SV]bIq:X6{X[;e+PsM/4f[G}=EUB< TUC 5~zhC&7&LJfW5 dnHV[ZD7t7YAW)%4U_+w ;^pD-< +l-n}RvSUrMLf,jPR9>K4h}(!J=#ld6fo:%'C7j&9i?`:=Q>?U/W*wFNb~V!UgvX/6~kGioD~5CPU_0FP-~h@e~/jN~`ozlggzaxarTUs7MfxF 0Kw?L0@+tY{+%Jlp 8!X|Jq/!(S/9<>I5(=n^TV:(;uer&TAVad6 nl"d`o%Z*G7x )+9ooi Wci-5PGqJ%_XD2h_6uATqTT!VJmX}d Afy #Doj2Ym6KmT!b `c_bqCayN#;1Aqp>OJmm(9L [g/[2DY.g tD ^]d&w2BE/T}vsUUX=F4I[|"TbK(.gX5vk!Ipb[z'];N5c2 pH +TV1]bnh${>E;VNULsK%q_@@z/) "X0qQ>U`6e@M/.a?37XvVbK:/#E 5VxsLCggq]o-+GZj;l%;`2hcS P"k`ODmvl`d?6yw4Copx cBq9e_p4Q/(wG^C ,Q-jpXb fmMvKJMY n:L^9Yt4{c0C^+9r+(W$>7,~ ^ ,Oogi9Uy1x.zH$jJJAG"YiYhB9g Wm]AkgY7g :a(!;5$W]6 %jp@"mM+y"+>`%qlp/1E;!wq5o+1V*Lk$-^ .e]vxB)(hUVUx~(VOYWg^^rYuVzgecHh ++l&V28_dvlWUgW&04E)&Zp9$I~~3CjfH[d3LqFK?a]q(x ]yF7Q{" 6r ueP]_8Rx2c0I<7-kJ]a O2e$5c(/3,|&gm3+>|8&pv,qq6M/vc@.r/`jM6o-'oeuR1=Ba!BfVa&F*w+e{[eGe}cEYun ;~;(/Cmo8bt9*w-{rf(yPS+*^(5O6sQC{(8 9:b*k+[a$`XxpYZ,&KrNUArxd95fVr^3a8 EPoUUiO6=P3>*m' 1"L}8uYxq^ )'mzc<'N'e;;,'wofWof Hke?|. P<2 Bor0yTN^+Y*<{S4EFd-f- [/7lP+h6""_x5Cu'Ke3>Sos'th(.L-*+%VK!pqiYWa=zKl!*<],P&7^/vXN{dubjk;79{~`Y63;4;vj~OWl% {%Ov 4c>~]%L8wL^>~P.+QjvJH(}-EGOL`W NHxPzmi&>c%_z[` Pf{}aaYV{:8Gkbkbe.{hw{)]]; 0(yv9(5L0%nv4JiB(]: iF4V}''MzO^"u+c5d,cZ ,A3*9!`C'}4Y`m{0VHo_37>{Cnx3<95Fv.{q(O33*-,u%o|7wYM, /B|>UOh*x"2!NYl"E~&-_c v;wKw8J*,6XE%_ |i[9.R nijjf:OK%wm%V@ roNMR7MP Haa&bP :H=q rDvmtHg-WPxFlN n!h7gTb=6Md ."Tc2z~a7Vb3vfFdja`$M&f nhqVO 0GzsrYIR"M|-5}w0CU&2C,oQ6V7Wv"7lK{ wyQ,{bo]h]Kue#0j Q/6N{I~j|hvQJ>H.la`khM3-{&v$%^Q?{#wH">HKw6 !f%O^B0Jl6e3v{xjTv~%1HtQvj-4;YLw

<>h){M[P!Rlsq2"4@m2(J[G@SEXDEyx= 70Womge#q`m[p' MOqR3 <[ez<_&xl e~#C< ;eyNC!RV&-#9S)}Vb1'~aDSov-N]}rF[&%&w8tT=(q-GCiVC1wzhgdk^K|m> t~4M~(FN,Bo>G+:e#T-"{I?Jm-c)RK4Tfj{lntcJ_> sQ}"e>?&fQ'5*mo=%~w|[31L~yz~yjto>2",*4nFU6R^{u~^$/uURs" `Y yS==/j^"|zj$(*` _5e7 f%B-<4')0|=tEUy1San}0v@{Y %Dp50 9lX8*vD]Za#N*A#+t]{aTZQc^DTVaQ 3j&;#g.da}_J4^Ja^6, _DHo(wiXZ]8Kb2pT :vDXTrT9$&43e!5J,1XP)mxJFyKQ$, F|n>~5n1n/D0"lOdZ]!3K_M`Q1KRfN}'9d88{nwBEvA#cQhNBQ`@|K][ h{.QNon(Sjf=5{&hm?! t[sBSTXrt <&%a#x)u~@wnJ+gm.!GNLbhl&je9`xig 9JCky GU ciyMoHVqhysm{F/tz}b6#8oBYdd0BK Gi1Z6gDy7]=n$E4x:QzpARAO(Y!H;T.$o_9/m F: XZCgW":0cA&xcW.1 wFxNz*Bg:Ire'J&LD)MT@px63a85!9u.[u2TA3C` xDqb{:Ab#sElr9t/LDXaX1b&ZM) +Nz MY,#Act5[3}4: 25c*k!*uTtpH8P_r1f+zHKw7s3q&X 4z+$8Cm8-B&x*jb?`YlEYt.A>-~I,f/%`C0eoI'*b1>@cH,ab UP;WB>m gm1x8k< ZBKY#*?h-G6BuWNr$hFK,w!o dD1 )M;q_`b.cn=(&ss x=5fVY9ATlvx'aD+* f}> (@`vM#(.:kpEIb>+Y"ap1RVk9phMw3XW>[e)CXv%3@9gi:e(;!V>1X}|FjL(Z%d,4-#4V@HaFIht_>^J[,K40D$w*^* {48iG+Q)/5Rt"^"SqL1-Q"%3W/k7`MKL+xPMVu*)h@s `2(k&aBaEy3^`n)5JC'vD&8GNL+hJ9{"r*ge!E(l3vFE9wQ<;x4:eWCx$SPC6fFc?#xNAS+GUF{K)2P&xxJi8bC?%0qY< 8-Iu(.I/w p ** V8TiE|]Et]69QC9 8A#dR&L yW9zY'>wjWRc9quBAb~&@{4Fp{ZVwF~S5M}e!:o&mOu^RF>mVC9M<7U+jdmvD)UNZIJ%WY~K>3,$Rhx}"J.ejO{,n~=-;K[vq?j,aT?>kW&@Rk%7% 1v:-o Zj)1nw< ny]K}.p}s#Xn*vOodw Z [M3CoDa zqD I"Sim VJj%oVV%9qHR.PyRe/F#&?Et5:Xa`8 fi`YQ&+mu~ra+e Nq2+o>QsfZ+<.]?IJ.V>,)- Y{|A-M*8ibYk.sNyqpMd)BhPeuOQ PxHb#(4&-Cw8A"Z5h[eREe:6FU"T0nsQ yHl6 wF'E! A3 4BUrHEt J MDS?+od,nU/$qOwv; V7:9w;7L"rU7*WE#yb8//i#&e oO_6(u:E"Pi]%fEeOr[NL5@nLcGj0zte<5y3 c,Nn9W.NBAf<]J>Vxc=Q1|?GX]w&U&OTGaNl7o+-FlS3^"e#Hyy8dk^S=7OE T%{=CL[zXeTgH,b+gl'((^%O~wuGG_8UyPe^^2SGr&U@$C4P4}u{w 4)`vFoY,S]S-Se$S}!khle) |00RY> .Ho|RX1=@NnYQvbG7302l#arzk y,M]/zA.Ta9#l^99Q9~I[:X /fFw^O'mHKfm/%&XkR@0>qs0ZP!Bea/O9:YXI2'.3O0Hs qr4Q]]$YF9>jP)3%b}W3}O# < C[@/I3)x.SQhx,F)$2` iBBfVSpxC'|dw{Ay%Vk2DX "-#'9BPp=j0:($u2_f4z~"cSx~U=lF*w+XMoRmOfc]kJHQp$P/=E s?sh#4 'B-;FY&VYa7ouc9v8_*{EF~5CinzF.r3?WpW(V6 k)uJ}gU& h+GRvx1E8C!%(; ]Bek*lo'rZw7 qxxeq4[8,U5iUNcbf"x" x` GhDG0ECC1!jx~0trBh,y;lM})~~#|~!kDfn:F73%YmC.8ITWCP`ifJNU@~K-R&Zx4QnUUY:gX]/5V}X*]`zBPqA )e!:1UcB:pZ&*t!tge_Q:z w<%P]"@f"7; kPIFR!L*PVa:WTJ|szi $8`'SEdSKdWo WtcdA1Hy[at+5W@[@1KW4&[`83RQAXHFT=@y7=Dx;a~|4Qo]OyV_n]^OD_'"J86rkR 1SeA7Hc^ #Q}z^o"KUP}SZdb0Q;i4XY1nNh/(6;8?,1Hm|hX+kVdw,N~pVD-Epb ;^ei52GPe+s/*:Laa92PF+^NVUU?UwX>ml",P5 u6{ aNP+O5(.fG,5_2ZzL

Read the rest here:
National Multiple Sclerosis Society Commits to $17 Million for 43 Research Projects - Multiple Sclerosis News Today